Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
LOBEF
)
0.0150
+0.0016 (+11.94%)
Streaming Delayed Price
Updated: 1:23 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about LOBEF
< Previous
1
2
Next >
Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
August 15, 2024
From
Lobe Sciences Ltd
Via
Business Wire
Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
August 12, 2024
From
Lobe Sciences Ltd
Via
Business Wire
Lobe Sciences Announces Update
June 04, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
March 01, 2023
By Richard Dal Monte
Via
TheNewswire.com
Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials
October 14, 2022
Canadian biotech company Lobe Sciences Ltd.
Via
Benzinga
Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
June 03, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
May 31, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
May 30, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
May 21, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
Lobe Sciences Provides Company Review of 2023
January 08, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Provides Update on L-130 Clinical Program
December 07, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
December 05, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
September 14, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
June 28, 2023
Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical...
Via
Benzinga
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
June 27, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer
June 07, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™
May 17, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
April 20, 2023
Orphan and rare diseases drug company Lobe Sciences Ltd. (OTCQB: LOBEF) is set to acquire Altemia & Company LLC.
Via
Benzinga
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
February 28, 2023
As early as the 1950s, scientists were researching the possible therapeutic benefits of psychedelics such as LSD and psilocybin mushrooms.
Via
Benzinga
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
January 27, 2023
Lobe Sciences (OTCQB: LOBEF), the psychedelics company performing drug R&D with sub-hallucinatory doses of psychedelics has signed a research agreement with headache medicine specialist Dr. Lauren R.
Via
Benzinga
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
January 26, 2023
Dr. Lauren R. Natbony to be Principal investigator Vancouver, BC – January 26, 2023 — Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a North American Biopharmaceutical company...
Via
FinancialNewsMedia
Exposures
Product Safety
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
January 19, 2023
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Trippy Trading: Top Psychedelic Stocks For 2023
January 17, 2023
When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus,...
Via
TheNewswire.com
Topics
Cannabis
Exposures
Cannabis
Lobe Sciences Announces Incorporation of Australian Subsidiary
September 23, 2022
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),...
Via
Newsfile
Lobe Sciences Announces Closing of Private Placement
September 08, 2022
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),...
Via
Newsfile
Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
September 01, 2022
Psychedelics biopharma company Lobe Sciences Ltd.
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.